Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072287 | 0.87 | NFE2L2 (0.60) | NFE2L2HRH3HPGDGRM2 | |
| SCHEMBL3079539 | 0.86 | NFE2L2 (0.58) | NFE2L2HRH3HPGDGRM2HRH2 | |
| SCHEMBL3085585 | 0.84 | HPGD (0.46) | NFE2L2HRH3ACHEHPGDGRM2 | |
| SCHEMBL27404013 | 0.75 | SLC18A3 (0.58) | HRH3CYP3A4CYP2C9 | |
| SCHEMBL3078119 | 0.74 | HRH3 (0.51) | HRH3HRH2HRH1 | |
| SCHEMBL3062765 | 0.72 | HRH3 (0.55) | HRH3HRH2HRH1 | |
| SCHEMBL3066092 | 0.72 | HPGD (0.50) | NFE2L2HRH3HPGDHRH2HRH1 | |
| SCHEMBL8495200 | 0.72 | IDO1 (0.44) | HRH3 | |
| SCHEMBL8496114 | 0.70 | NFE2L2 (0.52) | NFE2L2HRH3HPGDGRM2 | |
| SCHEMBL3072288 | 0.70 | NFE2L2 (0.59) | NFE2L2HRH3HPGDGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20050181984-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY | 2005-08-18 | — | — | US | disclosed |
| US-6916784-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030220236-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY | 2003-11-27 | — | — | US | disclosed |
| US-6384013-B1 | HETEROCYCLIC PEPTIDE FUNGICIDES | ELI LILLY AND COMPANY | 2002-05-07 | — | — | US | disclosed |
| US-5965525-A | FOR INHIBITING FUNGAL AND PARASITIC ACTIVITIES | ELI LILLY AND COMPANY (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0561639-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 1993-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220236-A1 | Cyclic peptide antifungal agents and process for preparation thereof | NGLY1, HM13, PTMS | NFE2L2 4709/4885HRH3 14/4885ACHE 4861/4885 |
| US-20050181984-A1 | Cyclic peptide antifungal agents and process for preparation thereof | NGLY1, PTMS, HM13 | NFE2L2 4824/4885HRH3 9/4885ACHE 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.